Want to see AU:BOT full AI Analyst Report?

Botanix Pharmaceuticals Limited (BOT) Price & Analysis

167 Followers

BOT Stock Chart & Stats

AU$0.04

>-AU$0.01(-1.09%)

At close: Jan 09 4:00 PM EST

AU$0.04

>-AU$0.01(-1.09%)

Day’s Range― - ―

52-Week RangeAU$0.02 - AU$0.35

Previous CloseN/A

Volume8.15M

Average Volume (3M)8.47M

Market Cap

AU$57.42M

Enterprise ValueAU$44.88M

Total Cash (Recent Filing)AU$31.61M

Total Debt (Recent Filing)AU$30.67M

Price to Earnings (P/E)―

Beta1.08

Next Earnings

Aug 28, 2026

EPS Estimate

-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding2,734,312,700

10 Day Avg. Volume7,344,780

30 Day Avg. Volume8,473,310

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)7.26

Price to Sales (P/S)101.98

P/FCF Ratio-7.49

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.57

Price Target Upside1325.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.01

Revenue Forecast (FY)AU$73.83M

Bulls Say, Bears Say

Bulls Say

Commercial Traction And Revenue GrowthSustained, rapid prescription and net revenue growth indicates clear product-market fit and accelerating market penetration. Over the next 2–6 months this reduces unit economics risk, supports payer engagement and distribution scale, and underpins a path to leverage fixed commercial costs.

Scalable Fulfillment Platform (SendRx)A high-performing, scalable fulfillment platform that materially improves fill, reimbursement and adherence creates durable commercial advantage. It lowers variable selling costs per script, improves gross‑to‑net economics and can support additional products without proportional R&D spend.

Strong IP Runway And Large Addressable MarketLong exclusivity to 2040 and a multi‑million patient TAM provide structural revenue longevity and pricing leverage. This supports multi-year commercialization returns and positions the asset as an attractive strategic target or licensing opportunity for partners and acquirers.

Bears Say

Severe Cash Burn And Financing DependenceVery large negative operating and free cash flow creates structural dependence on external capital. With cash runway constrained and a partially completed raise, the company faces dilution and execution risk if market access tightens or if revenue growth lags, impacting long‑term funding flexibility.

Material Operating Losses And High Commercial SpendSubstantial recurring operating losses driven by elevated commercial investment mean profitability depends on sustained revenue scale. If adoption, reimbursement or COGS improvements underperform, the cost base will continue to outpace revenues, pressuring margins and cash needs.

Single‑source API And Contracted Purchase ObligationsDependence on one API supplier plus near‑term contractual purchases creates supply and timing risk. Qualifying alternate suppliers requires time and capital; any disruption or delay could halt shipments, raise COGS, or force costly spot buys, threatening revenue continuity and margins.

Botanix Pharmaceuticals Limited News

Botanix Seeks ASX Quotation for 10.3 Million New Shares

An update from Botanix Pharmaceuticals Limited ( ($AU:BOT) ) is now available. Botanix Pharmaceuticals has applied for quotation...

1M ago

Botanix Securities Lapse Trims Potential Share Dilution

An update from Botanix Pharmaceuticals Limited ( ($AU:BOT) ) is now available. Botanix Pharmaceuticals has notified the market...

1M ago

Botanix Sets Stricter Securities Trading Rules to Bolster Market Confidence

The latest update is out from Botanix Pharmaceuticals Limited ( ($AU:BOT) ). Botanix Pharmaceuticals has formalized a securities...

2M ago

Botanix Shifts Registered Office to Melbourne as It Advances Hyperhidrosis Drug

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) just unveiled an update. Botanix Pharmaceuticals has relocated its registered office, principal...

2M ago

Botanix Taps Veteran Executive Paul Seaback as Chief Operating Officer

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) just unveiled an announcement. Botanix Pharmaceuticals has promoted Paul Seaback to Chief...

2M ago

Botanix issues investor update with detailed disclaimers and risk caveats

The latest update is out from Botanix Pharmaceuticals Limited ( ($AU:BOT) ). Botanix Pharmaceuticals has issued an investor...

2M ago

Botanix builds Sofdra momentum, fortifies balance sheet and supply chain

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has provided an announcement. Botanix reported continued growth in Sofdra prescriptions in...

2M ago

Botanix Director Granted Options Linked to Share Placement

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has provided an announcement. Botanix Pharmaceuticals has disclosed a change in the...

2M ago

Botanix Opens Investor Webinar to Detail Sofdra Progress and Quarterly Performance

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) just unveiled an update. Botanix Pharmaceuticals has opened registration for an investor...

2M ago

Botanix Issues 773 Million Unlisted Options at $0.06 Expiring 2027

The latest announcement is out from Botanix Pharmaceuticals Limited ( ($AU:BOT) ). Botanix Pharmaceuticals has notified the market...

3M ago

BOT FAQ

What was Botanix Pharmaceuticals Limited’s price range in the past 12 months?

Botanix Pharmaceuticals Limited lowest share price was AU$0.02 and its highest was AU$0.35 in the past 12 months.

What is Botanix Pharmaceuticals Limited’s market cap?

Botanix Pharmaceuticals Limited’s market cap is AU$57.42M.

When is Botanix Pharmaceuticals Limited’s upcoming earnings report date?

Botanix Pharmaceuticals Limited’s upcoming earnings report date is Aug 28, 2026 which is in 55 days.

How were Botanix Pharmaceuticals Limited’s earnings last quarter?

Botanix Pharmaceuticals Limited released its earnings results on Feb 27, 2026. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.007.

Is Botanix Pharmaceuticals Limited overvalued?

According to Wall Street analysts Botanix Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Botanix Pharmaceuticals Limited pay dividends?

Botanix Pharmaceuticals Limited does not currently pay dividends.

What is Botanix Pharmaceuticals Limited’s EPS estimate?

Botanix Pharmaceuticals Limited’s EPS estimate is -0.01.

How many shares outstanding does Botanix Pharmaceuticals Limited have?

Botanix Pharmaceuticals Limited has 2,734,312,700 shares outstanding.

What happened to Botanix Pharmaceuticals Limited’s price movement after its last earnings report?

Botanix Pharmaceuticals Limited reported an EPS of -AU$0.017 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Botanix Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in AU:BOT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Botanix Pharmaceuticals Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-131.13%

Trailing 12-Months

Asset Growth

-0.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespread skin conditions and various infections. Its robust developmental portfolio showcases several key assets: Sofpironium Bromide, which has successfully completed Phase 3 clinical studies for managing primary axillary hyperhidrosis; BTX 1503, a transdermal gel designed to tackle severe acne in both adults and teenagers, having concluded Phase II trials; BTX 1801, which has progressed through Phase IIb clinical investigations for infections caused by Staphylococcus aureus (including its methicillin-resistant variant); BTX 1702, currently undergoing Phase IIb clinical evaluation for papulopustular rosacea; and BTX 1204A, targeting atopic dermatitis. Established in 1984, Botanix Pharmaceuticals operates from its headquarters in Leederville, Australia.

Botanix Pharmaceuticals Limited (BOT) Earnings & Revenues

Historic Earnings Reports

BOT Stock 12 Month Forecast

Average Price Target

AU$0.57

▲(1325.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"AU$2","-1":"-AU$1","-0.25":"-AU$0.25","0.5":"AU$0.5","1.25":"AU$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$1.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.14</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.022,0.09723076923076923,0.17246153846153844,0.24769230769230768,0.3229230769230769,0.39815384615384614,0.4733846153846154,0.5486153846153846,0.6238461538461538,0.699076923076923,0.7743076923076923,0.8495384615384615,0.9247692307692308,{"y":1,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.022,0.06415384615384614,0.1063076923076923,0.14846153846153842,0.19061538461538458,0.23276923076923073,0.2749230769230769,0.31707692307692303,0.3592307692307692,0.40138461538461534,0.4435384615384615,0.48569230769230765,0.5278461538461537,{"y":0.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.022,0.03107692307692308,0.04015384615384615,0.04923076923076923,0.05830769230769231,0.06738461538461539,0.07646153846153847,0.08553846153846154,0.09461538461538463,0.1036923076923077,0.11276923076923079,0.12184615384615385,0.13092307692307692,{"y":0.14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.145,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.145,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.155,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.053,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.045,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.027,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.024,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.022,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >